Literature DB >> 16388933

Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade.

Michael Diamond1, John P Kelly, Thomas J Connor.   

Abstract

In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood. In addition, we examined the ability of trimipramine; a tricyclic antidepressant that is devoid of monoamine reuptake inhibitory properties on cytokine production. Lipopolysaccharide (LPS) was used to stimulate monocyte-derived pro-inflammatory (IL-1beta, TNF-alpha, IL-12) and anti-inflammatory (IL-10) cytokines, whilst concanavalin A (Con A) was used to stimulate T-cell (Th(1): IFN-gamma and Th(2/3): IL-10) cytokines. All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for serotonin or noradrenaline transporters. This suppression of IFN-gamma production was paralleled by reduced T-cell proliferation, therefore we suggest that the ability of antidepressants to suppress IFN-gamma production may be related to their anti-proliferative properties. The fact that trimipramine also suppressed IFN-gamma production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake. Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived IL-10 production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and desipramine. In contrast to the robust actions of antidepressants on T-cell derived cytokine production, they failed to induce any consistent change in LPS-induced monocyte cytokine production. Overall, our results indicate that IFN-gamma producing T-cells (Th(1) cells) are the major target for the immunomodulatory actions of antidepressants, and provide evidence questioning the relationship between the monoaminergic reuptake properties of antidepressants and their immunomodulatory effects. The potential clinical significance of the anti-inflammatory actions of antidepressants is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388933     DOI: 10.1016/j.euroneuro.2005.11.011

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  33 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

2.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Shvetank Bhatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

3.  Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes.

Authors:  Luciana S Branco-de-Almeida; Mikihito Kajiya; Cristina R Cardoso; Marcelo J B Silva; Kouji Ohta; Pedro L Rosalen; Gilson C N Franco; Xiaozhe Han; Martin A Taubman; Toshihisa Kawai
Journal:  FEMS Immunol Med Microbiol       Date:  2011-06-16

4.  Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial.

Authors:  Bharathi S Gadad; Manish K Jha; Bruce D Grannemann; Taryn L Mayes; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2017-05-26       Impact factor: 4.791

5.  Desipramine decreases expression of human and murine indoleamine-2,3-dioxygenases.

Authors:  Alexandra K Brooks; Tiffany M Janda; Marcus A Lawson; Jennifer L Rytych; Robin A Smith; Cecilia Ocampo-Solis; Robert H McCusker
Journal:  Brain Behav Immun       Date:  2017-02-16       Impact factor: 7.217

6.  Fluoxetine inhibits inflammatory response and bone loss in a rat model of ligature-induced periodontitis.

Authors:  Luciana S Branco-de-Almeida; Gilson C Franco; Myrella L Castro; Juliana G Dos Santos; Ana Lia Anbinder; Sheila C Cortelli; Mikihito Kajiya; Toshihisa Kawai; Pedro L Rosalen
Journal:  J Periodontol       Date:  2011-10-03       Impact factor: 6.993

Review 7.  Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?

Authors:  Karen Wager-Smith; Athina Markou
Journal:  Neurosci Biobehav Rev       Date:  2010-09-29       Impact factor: 8.989

8.  Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.

Authors:  Joseph R Podojil; Mahesh V Padval; Stephen D Miller
Journal:  Cell Immunol       Date:  2011-05-31       Impact factor: 4.868

9.  Fluoxetine reduces murine graft-versus-host disease by induction of T cell immunosuppression.

Authors:  Veerle Gobin; Katleen Van Steendam; Sabine Fevery; Kelly Tilleman; An D Billiau; Damiaan Denys; Dieter L Deforce
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-04       Impact factor: 4.147

10.  Antenatal depression, psychotropic medication use, and inflammation among pregnant women.

Authors:  Emily S Miller; William A Grobman; Jennifer Culhane; Emma Adam; Claudia Buss; Sonja Entringer; Gregory Miller; Pathik D Wadhwa; Lauren Keenan-Devlin; Ann Borders
Journal:  Arch Womens Ment Health       Date:  2018-06-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.